Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
Date:11/9/2009

NEW YORK, Nov. 9 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease (the "Company"), today announced its results for the third quarter ended September 30, 2009.

At September 30, 2009, the Company had cash, cash equivalents, interest receivable and investment securities of $41.0 million, as compared to $22.7 million at December 31, 2008. On September 30, 2009, the Company completed a $20.0 million registered direct offering of common stock and warrants, which provided proceeds to the Company of approximately $18.4 million, net of offering costs of approximately $1.6 million which were paid subsequent to September 30, 2009.

The net income for the third quarter ended September 30, 2009, was $0.6 million, or $0.01 per diluted share, compared to a net loss of $6.8 million, or $0.15 per diluted share, for the third quarter in 2008. The change in net income (loss) was primarily attributable to the recognition of $3.5 million in other revenue, related to the settlement of a dispute with the former licensor of Sulonex (sulodexide), in July 2009, over issues arising from the terminated license agreement, a $1.4 million decrease in other selling, general and administrative expenses, and a $1.4 million decrease in non-cash compensation expense related to equity grants.

The net income for the nine months ended September 30, 2009, was $15.1 million, or $0.31 per diluted share, compared to a net loss of $49.1 million, or $1.11 per diluted share, for the comparable period in 2008. The change in net income (loss) was primarily attributable to a $26.9 million decrease in research and developm
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
2. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
3. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
4. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
5. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
6. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
8. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015 The quantum dot market report analyzes ... market based on the product includes medical devices, display, and ... lighting, battery and energy storage, QD laser, and transistor. The ... the quantum dot market. The report also provides the geographic ... , Europe , Asia-Pacific ...
(Date:9/2/2015)... YORK , Sept. 2, 2015   About ... the most common laboratory technologies that is used for ... antibodies in solution. ELISA test uses various types of ... phosphatases and the result is detected by photometry or ... the treatment of various infectious diseases such as HIV, ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced the ... Switzerland - November 26-27, 2015)" conference to their offering. ... of the key areas of pharmaceutical regulatory affairs in ... Macau and Taiwan ... aspects of gaining and maintaining a successful Marketing Authorisation in ...
Breaking Medicine Technology:Quantum Dot Market by Product , Material, Application, and Geography- Forecast up to 2020 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 2Global Enzyme-Linked Immunosorbent Assay (Elisa) Testing Market 2015-2019 3Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
... Feb. 14, 2011 McNicoll, Lewis & Vlak LLC ... industries, announced today that Caroline Corner, Ph. D. has ... where she will cover the Medical Devices and Diagnostics ... (Logo: http://photos.prnewswire.com/prnh/20100920/NY67927LOGO) "The addition of ...
... HILL, N.C., Feb. 14, 2011 Thought Leader Select, ... the biopharmaceutical industry and the medical community, announces the ... blog Marketing4Health . The research ... to become the blog,s exclusive sponsor, beginning ...
Cached Medicine Technology:Medical Devices and Diagnostics Analyst Joins MLV to Further Expand its Coverage of the Life Sciences Sector 2Thought Leader Select Announces Media Partnership with Marketing4Health 2
(Date:9/3/2015)... ... , ... Dr. Robert Winchell has been appointed director of the Trauma Center ... Cornell Medical Center, effective July 27. He will serve on the faculty of Weill ... the critically injured and the development, design and operations of trauma systems. As chief, ...
(Date:9/3/2015)... ... September 03, 2015 , ... Atlantic Information Services, Inc. (AIS) ... Benefit Strategies for a Rapidly Changing Marketplace.” In this Sept. 16 program, pharmacy ... discuss how plan sponsors are adopting bold, innovative strategies to control soaring specialty ...
(Date:9/3/2015)... CA (PRWEB) , ... September 03, 2015 , ... ProScrub ... easily create back & forth, flicker, repeat, and custom speed effects without the use ... and the speed of effect. ProScrub tools are perfect complements to energetic video ...
(Date:9/3/2015)... ... September 03, 2015 , ... “Love in Tokyo” an independent romantic ... , and Amazon and will be released on DVD early next year, ... a Foreigner,” Itsuka, an actress and singer/songwriter, and Jason London, lead from “Dazed and ...
(Date:9/3/2015)... WI (PRWEB) , ... September 03, 2015 , ... At ... after becoming dissatisfied with the traditional health care model, where the primary care physician ... of individuals who want to become educated about their health issues and empowered to ...
Breaking Medicine News(10 mins):Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 2Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 3Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 4Health News:Trauma Expert Joins NewYork-Presbyterian Hospital and Weill Cornell Medical College 5Health News:Speakers for Upcoming AIS Virtual Conference on Pharmacy Benefit Strategies Include Executives from CVS Health, Express Scripts 2Health News:FCPX Effects Developer Releases ProScrub for Final Cut Pro X 2Health News:The Romantic Comedy Film "Love in Tokyo" Has Been Released on ITunes, Google Play, and Amazon 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 2Health News:Men Dissatisfied with the Primary Care Physician’s Approach to Andropause Are Turning to Renew Man™ 3
... Diabetes Will Meet Nick Jonas in Los Angeles and,Become ... N.Y., Oct. 30 To kick off Diabetes Awareness,Month, ... have,won the opportunity to meet teen pop sensation Nick ... In Nick,s Shoes" (W.I.N.S.),sweepstakes. These Grand Prize winners will ...
... last Sunday in March increases the risk of myocardial infarction ... in the autumn reduces the risk, albeit to a lesser ... the prestigious New England Journal of Medicine . , ... myocardial infarction in Sweden has changed with the summer and ...
... off American,Diabetes Month this November, the American Diabetes ... along with Eli,Lilly and Company,s national educational initiative, ... Update, an educational program for people affected by ... November 1, at the Greater,Grace Temple, 23500 W. ...
... Resource for Sharing Product, Educational Expertise,with ASCs, ... Braun Medical Inc. (B.,Braun) has launched a ... educational and editorial information for ambulatory surgical ... The new online resource, http://www.asc.bbraunusa.com, ...
... First Company to Reach Pivotal Study for Spine Nucleus ... Technology,Inc. announced today, the U.S. Food and Drug Administration ... the NuBac(R) Nucleus,Replacement Device for the spine., Pioneer,s ... MD, MBA,says, "This is a huge milestone and accomplishment ...
... Therapeutics,Inc. (OTC Bulletin Board: ARNI.OB), a clinical-stage biopharmaceutical,company ... William F. Hamilton, Ph.D. to its Board of ... Hamilton has over 40 years experience as a,professor ... the areas of,technology strategy and planning, entrepreneurship and ...
Cached Medicine News:Health News:Bayer Diabetes Care Names 'Walk In Nick's Shoes' (W.I.N.S.) Sweepstakes Grand Prize Winners 2Health News:Bayer Diabetes Care Names 'Walk In Nick's Shoes' (W.I.N.S.) Sweepstakes Grand Prize Winners 3Health News:Clock-shifts affect risk of heart attack 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 2Health News:American Diabetes Association and Eli Lilly and Company Unite to Educate and Empower African-Americans with Diabetes 3Health News:B. Braun Medical Inc. Launches Ambulatory Surgical Center Website 2Health News:Pioneer(R) Surgical Technology's NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study 2Health News:Pioneer(R) Surgical Technology's NuBac(R) Nucleus Replacement Device Wins FDA Approval for IDE Pivotal Study 3Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 2Health News:Arno Therapeutics Appoints William F. Hamilton to Board of Directors 3
... Units With Titanium Staples for use with ... Titanium Staples)., ,The Auto Suture™ MULTIFIRE ... staplers with MULTIFIRE GIA™ 60 and 80 ... Suture™ MULTIFIRE SGIA™ 60 knifeless single use ...
... The PROXIMATE HCS Procedure for Prolapse and ... of titanium staples in 33mm diameter size. ... canal for transection and resection of internal ... surgical treatment of hemorrhoidal disease. The PPH01 ...
... ILS Staplers are anastomotic staplers available in ... instrument to lumen diameter. The staplers permit ... to improve access and ease of use. ... tissue compression by adjusting the height of ...
ENDOPATH ILS Circular Sizer Set for ILS circular staplers. , ,The ILS Circular Sizer Set is intended to aid in selecting the appropriate size ILS Intraluminal Stapler for use in a variety of applica...
Medicine Products: